Navigation Links
Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations
Date:11/3/2009

a spin-off of the Cleveland Clinic Foundation. Primary investors in the company include Southwest Michigan First Life Sciences Fund, Triathlon Medical Venture Partners, Hopen Therapeutics and the Michigan Economic Development Corporation. Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often associated with immunotherapy. The company is focusing on commercializing therapeutic monoclonal antibody technology for the transplantation and autoimmune markets. Additional information concerning the company and its technology can be found on its website www.tolera.com.

SOURCE Tolera Therapeutics, Inc.


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
5. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
11. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... MRIGlobal, an internationally recognized research and development organization ... has appointed Richard A. Winegar, Ph.D., to Principal Advisor ... Dr. Winegar is a recognized expert in ... genetic toxicology.  As Principal Advisor for Science, he will ...
... July 11, 2011 Avisena, one of the nation,s ... for physician practices, today announced the extension of a ... facility will be used to accelerate the Company,s strategic ... and marketing. "Square 1 believes in supporting ...
... Pharma, Inc. is pleased to announce that it has ... its lead drug for the treatment of stroke and ... A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single ... of Oral and Intravenous Administration of Methamphetamine Hydrochloride in ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank 2Sinapis Pharma Completes Phase I Trial 2
(Date:7/14/2014)... oxygen control insect body size? What influence does genetics have ... of Current Opinion in Insect Science launched ... Current Opinion in Insect Science is the latest ... review journal that aims to provide specialists with a unique ... published in the field of insect science. First articles published ...
(Date:7/14/2014)... with roots in the local environment manage much better ... from foreign environments. , A world without bees ... Denmark alone an additional 600 million to 1 billion ... done by bees making honey and pollinating a wide ... , Unfortunately, bees all over the world are under ...
(Date:7/14/2014)... genes that improved the harvesting of sunlight, a new ... genomes reveals. The findings could help current efforts to ... a ,genetic snapshot, of maize as it existed 10 ... of its genome a ,whole genome duplication, event. ... ,copied, genes to cope with the pressures of domestication, ...
Breaking Biology News(10 mins):Best for bees to be stay-at-homes 2A-maize-ing double life of a genome 2
... gases and increase production at the same time has been ... Industries' (DPI) Wollongbar Agricultural Institute. , Trials of agrichar - ... and the environment - have doubled and, in one case, ... tonnes per hectare. , Agrichar is a black ...
... tiger now occupies a mere 7 percent of its historic ... has declined by 41 percent over the past decade, according ... BioScience. Growing trade in folk medicines made from tiger parts ... believed to be the chief reason for the losses. The ...
... long been clear that smoking causes cancer, but new research ... who smokes. , Canadian researchers have demonstrated in ... of sperm cells, alterations that could potentially be inherited by ... June 1 issue of Cancer Research, a journal of the ...
Cached Biology News:Soils offer new hope as carbon sink 2Soils offer new hope as carbon sink 3Threats to wild tigers growing 2Cigarette smoke alters DNA in sperm, genetic damage could pass to offspring 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... Kit, 100 reactions. Prepare circular DNA ... h.Generate microgram quantities of template DNA ... amplified DNA directly for cycle sequencing ... M13 liquid cultures, colonies, plaques, or ...
Biology Products: